PTSD Resources – Myself – Relatix Health

Overview

Post-traumatic stress disorder (PTSD) can develop after an experience involving serious danger, violence, sexual assault, injury or death. You may find that the event has ended, but your brain and body continue to respond as though danger could return at any moment. Memories may intrude without warning, sleep can become exhausting, and situations that once felt ordinary may produce an immediate physical alarm response. Some people experience anger or intense fear; others feel numb, disconnected or unusually alert to everything happening around them.

PTSD can begin in childhood, or emerge later following traumatic experiences during childhood. If it began very early, you may have grown up expecting danger, struggling with sleep or finding it difficult to trust people. There may be no clear memory of how life felt before those responses developed. Repeated childhood trauma can also contribute to complex PTSD, which may involve additional difficulties with emotion regulation, relationships and self-perception. Childhood-onset PTSD and complex PTSD are not interchangeable diagnoses.

People differ biologically in their susceptibility to PTSD. Large genetic studies identify inherited variations affecting neuronal signalling, brain development and stress-related pathways. Researchers have also measured differences in threat-related brain activity before people encounter later traumatic events. Traumatic exposure can then change memory processing, arousal and the way the brain distinguishes present safety from past danger. Your particular combination of changes may differ considerably from someone else’s (Nievergelt et al., Nature Genetics, 2024; Biological Psychiatry, 2025).

PTSD can seriously affect work, physical health, friendships and intimate relationships. It can also improve, including after many years. Treatments that help the brain learn new responses to traumatic memories have produced substantial benefits in randomised clinical trials. Research into MDMA, psilocybin and other biological approaches is expanding the possibilities further, although these newer interventions have very different levels of evidence.

On this page: Early warning signs · How to get diagnosed? · Life trajectory · Things you might need to work on · Workplace success · Family dynamics · Friendship & social skills · Intimate relationships · Self-help & coping · How it can be for Them to interact with You · Learn more (the Science) · Organisations · Resources · Other people like you

Early warning signs

Immediately after trauma, disturbed sleep, recurring memories and heightened alertness can be common. In many people these gradually diminish. PTSD becomes more likely when the responses persist, become more disruptive or intensify over time.

You might notice:

Intrusive memories or flashbacks. Images, sounds, sensations or fragments of the experience come back unexpectedly. Sometimes your body reacts before you recognise what reminded you of the event.
Nightmares and disrupted sleep. You may dread falling asleep, wake suddenly or feel exhausted despite spending hours in bed.
A nervous system on high alert. You startle easily, scan for exits, monitor people’s expressions or feel unable to relax in places that others find comfortable.
Avoidance. You may take longer routes, refuse invitations, avoid certain people or places, or keep yourself constantly occupied to prevent memories returning.
Changes in mood, concentration and memory. Irritability, sadness, guilt, reduced enjoyment, difficulty concentrating or gaps in recall can appear alongside the more obvious fear responses.
Feeling distant or unreal. Some people experience dissociation: sounds seem far away, time feels strange, or they feel detached from their body or surroundings.
Physical reactions. A racing heart, sweating, nausea, muscle tension or an urge to escape may occur in response to a particular reminder.

The timing varies. Some people experience persistent symptoms soon after an event; for others, serious difficulties emerge months or even years later.

When PTSD begins in childhood

As a child, you might have had nightmares, stomach aches, a strong startle response, difficulty concentrating at school, sudden anger or a need to know where adults were at all times. Younger children sometimes repeat parts of a frightening experience in play or become clingy; teenagers may withdraw, take more risks or become easily irritated. Trauma-related restlessness and concentration problems can resemble ADHD, and both conditions can also occur together (US National Center for PTSD, 2026; CDC, 2026).

If those responses continued into adulthood, they may feel like your ordinary way of being rather than symptoms that started on a particular date. You might recognise them now through patterns in sleep, relationships, physical tension or the situations you avoid.

It may help to recognise your sequence. Perhaps sleep deteriorates first, or a smell causes an immediate bodily reaction before any conscious memory appears. Such patterns can guide treatment.

How to get diagnosed?

PTSD is assessed through four main groups of symptoms that develop after exposure to a traumatic event:

Re-experiencing: unwanted memories, nightmares, flashbacks or strong emotional and physical reactions to reminders.
Avoidance: staying away from memories, conversations, situations or places associated with the experience.
Changes in mood and thinking: persistent negative emotions, loss of interest, detachment, difficulty remembering aspects of the event or altered expectations about danger.
Changes in alertness and reactions: hypervigilance, exaggerated startle responses, irritability, poor concentration, sleep difficulties or risk-taking behaviour.

For a PTSD diagnosis, the symptoms generally persist for more than a month and significantly affect everyday functioning. A clinician assesses what happened, the symptoms you experience, their timing and how they affect work, relationships, sleep and health. You do not need to remember or describe every detail of a traumatic experience in the first appointment (VA/DoD PTSD clinical guideline, 2023).

After repeated or prolonged traumatic experiences, some people also have persistent difficulties regulating emotions, feeling connected to others or maintaining a stable sense of themselves. Clinicians may assess complex PTSD, which is separately recognised in the international ICD-11 classification. Complex PTSD can follow childhood trauma, but also prolonged trauma in adult life; experiencing childhood trauma does not automatically mean you have complex PTSD.

An assessment should distinguish PTSD that was already present in childhood, PTSD recognised in adulthood after childhood experiences, and symptoms arising after more recent events. This helps establish what has been happening across your life, including effects on education, friendships, sexuality and everyday functioning. When assessing a child, clinicians use age-appropriate interviews and consider symptoms that look different from adult PTSD, including changes in play and behaviour. Dissociation, depression, panic, prolonged grief, brain injury, medication effects and substance use may also need assessment; several can coexist.

Structured interviews and validated questionnaires, such as the PTSD Checklist (PCL-5) and the Clinician-Administered PTSD Scale (CAPS-5), help measure symptoms and follow change over time. Genetic profiles, cortisol measurements and functional MRI can reveal biological associations with PTSD, but none has yet been validated as a standalone diagnostic test for an individual.

If you are seeking an assessment, it can be useful to note which experiences are most disruptive: nightmares, unwanted memories, losing concentration, avoiding people, becoming intensely alert or feeling disconnected. Include their effect on an ordinary week. A good assessment should lead to a discussion of treatments that address those specific problems.

Life trajectory

PTSD has several possible courses. Some people recover within months, some improve gradually over years, some experience long periods of persistent symptoms, and others become more affected later. Symptoms can improve even after decades.

A 2025 study analysed more than 81,000 assessments from 12,822 World Trade Center responders over approximately 20 years. Among responders with PTSD, the median time to a substantial symptom improvement was around nine years. Many improved over the two decades, while approximately one in ten continued to experience elevated symptoms or worsening at the end of follow-up. The study describes the natural course under varied circumstances, not the effect of one particular treatment (Mann et al., Nature Mental Health, 2025).

Clinical trials give another reason for optimism. In a study of 916 veterans receiving prolonged exposure therapy or cognitive processing therapy, 72.1% and 64.9%, respectively, showed meaningful symptom improvement at six months. 37.6% and 28.9% no longer met the study’s PTSD diagnostic criteria, although the proportion reaching the stricter definition of full remission was lower. Both treatments helped, and treatment completion was a significant challenge (Schnurr et al., JAMA Network Open, 2022).

PTSD that began in childhood can also improve. A 2025 review combined 70 randomised trials involving 5,528 children and adolescents. Trauma-focused cognitive behavioural therapy produced large average reductions in PTSD symptoms compared with control groups, including benefits that persisted at later follow-up. Early symptoms can interfere with learning and friendships, but effective treatment during childhood or adolescence can reduce their impact. Adults with childhood-onset PTSD can also benefit from treatment; progress may involve changing responses that have felt familiar for many years (Hoppen et al., JAMA Psychiatry, 2025).

PTSD is also associated with serious long-term health risks. A 2026 national study following 28,777 people with PTSD found approximately 32% higher overall mortality risk than in a matched comparison group after adjustment. Much of the excess came from suicide and other unnatural causes, including accidents. The study did not find a consistent increase in natural-cause mortality after adjustment; the results do not translate into a fixed number of years lost for an individual (Hsu et al., Epidemiology and Psychiatric Sciences, 2026).

Long-term health therefore deserves attention alongside PTSD symptoms: sleep, cardiovascular health, injuries, alcohol and drug use, depression, and suicidal thoughts. Research also finds associations between PTSD symptoms and accelerated epigenetic ageing, although it has not yet shown that treatment reverses those ageing markers (Bourassa et al., Biopsychosocial Science and Medicine, 2025).

Progress may mean fewer nightmares, returning to a job, enjoying physical intimacy or feeling settled at home. Improvement may appear in one area before another.

Things you might need to work on

PTSD often involves patterns that once helped you respond to danger but now appear in situations where you would like to feel comfortable. You may recognise several areas worth working on:

Recognising alarm signals and reminders. Notice changes in breathing, muscle tension or the urge to leave. A sound or smell may produce an immediate physical reaction; treatment can help you distinguish the memory of danger from present circumstances.
Reducing avoidance gradually. Avoidance can bring rapid relief, but it may also shrink your life. Trauma-focused treatment helps you approach reminders and ordinary activities at a manageable pace.
Restoring sleep. Nightmares, insomnia and repeated awakenings can make the following day’s symptoms substantially harder to manage.
Working with anger and concentration. Persistent alertness can make conversation, driving, reading or decision-making tiring.
Recognising alcohol or drug use as part of the pattern. If you use substances to sleep, settle your nerves or avoid memories, treating PTSD and substance use together may be particularly helpful.
Rebuilding activities you miss. Choose a specific goal, such as taking a train or meeting a friend, and identify what is getting in the way.

If PTSD began when you were growing up, identifying what feeling safe is like may be part of the work. Rather than returning to a remembered earlier self, you may be learning ways of sleeping, relaxing, disagreeing or getting close to people that you have rarely experienced. You do not need to recreate a traumatic event on your own. Evidence-based trauma-focused treatment is structured and collaborative, with attention to your current safety.

Workplace success

PTSD can have considerable consequences for employment. You may be highly capable at the work itself but find commuting, busy rooms, unpredictable noises, certain responsibilities or conflicts exhausting. Poor sleep and persistent physiological arousal can reduce concentration and stamina. Some people leave jobs or avoid promotion because the working environment repeatedly activates their threat responses.

Work may become easier if you can identify the specific difficulty rather than simply trying to endure an exhausting working day:

Ask for a quieter workspace or predictable tasks if noise and unpredictability are disruptive.
Where possible, take a short break after a strong physiological reaction and return when you can concentrate.
If shift work worsens nightmares or sleep loss, explore alternative schedules.
Use written priorities when memory and concentration are affected.
Decide privately what medical information, if any, you want to share with an employer. Practical workplace adjustments do not always require a detailed account of trauma.

Treatment may improve your ability to work, but employment outcomes depend on the job, the severity of symptoms, other health conditions and the support available. Financial stability and an appropriate working environment are important outcomes in their own right.

Family dynamics

Your family may notice that you sleep differently, withdraw from activities, become irritated more quickly or react strongly to something that seems ordinary to them. They may have little idea which sights, noises or interactions produce an immediate alarm response for you.

You can help people close to you understand what you actually experience. For example: “That sound reminds me of what happened, and my heart starts racing. I need a little time before I can talk normally again.” A short, specific explanation is often more useful than expecting someone to infer what is happening.

Where it helps, agree on practical arrangements around sleep, noise, privacy, shared responsibilities and what you prefer when you become overwhelmed. Some people welcome physical closeness; others need space. Preferences may change during recovery.

If a partner, parent or other relative wants to help with treatment, you can decide together whether to include them in a session or share information about the approach. Family members also have their own needs and may benefit from independent support, particularly when symptoms have affected life together for many years.

When PTSD is linked to childhood experiences, family relationships may be more complicated. Some relatives may have offered safety and support; others may be connected to what happened. You can build support with people you trust, and treatment does not require reconnecting with an unsafe relative. If you are currently a parent, you may also want help recognising how your own alarm responses affect daily family routines or moments of conflict.

Friendship & social skills

PTSD can make social life difficult in ways that other people do not immediately recognise. You may cancel plans because you slept badly, avoid crowded places, stop replying to messages or feel unusually alert to other people’s expressions. A sudden noise or unexpected touch may change your mood in an instant.

Friends might experience this as withdrawal, unpredictability or a loss of interest in the friendship. Over time, repeated cancellations or angry exchanges can cause real distance. That can be painful, especially if isolation develops when you would most benefit from ordinary company.

It may help to choose settings in which you can actually enjoy meeting people: a quiet café instead of a crowded bar, a walk instead of a noisy event, or a short visit rather than an exhausting evening. You can explain that sleep or particular environments have been difficult without describing private traumatic experiences.

Where a relationship has become strained, a direct conversation may help: “I know I’ve cancelled several times. I do want to see you. Could we try somewhere quieter next week?” Some friendships can be rebuilt; others may change or end.

Intimate relationships

PTSD can affect romantic relationships through changes in sleep, alertness, trust, concentration, mood and physical closeness. You might want intimacy but find your body becomes tense during touch, feel disconnected during a conversation or need more control over when and where closeness happens. If these responses began in childhood, you may have spent years learning to monitor other people’s moods before paying attention to what you want from closeness.

Partners may find it difficult when an ordinary disagreement produces a much stronger reaction than expected, or when periods of withdrawal continue for days. It helps to discuss what each of you notices without making every interaction about PTSD. You may want your partner to ask whether you’re feeling okay, offer quiet company, or leave you some space; they may need to tell you how your reactions affect them too.

Sex and physical intimacy

PTSD is associated with changes in sexual desire, satisfaction and functioning. Symptoms such as avoidance and heightened alertness may affect arousal or enjoyment. Trauma involving sexual violence can make particular situations, sensations or kinds of touch especially difficult, although this is not everyone’s experience. A recent study also associated PTSD symptom burden and avoidance with poorer sexual functioning (Jakubowski et al., 2026).

You can talk about what feels comfortable, whether you prefer affection without sex at certain times, and whether some forms of touch or surprise are unwelcome. Consent, comfort and mutual enthusiasm matter every time. If you feel dissociated, very distressed or affected by alcohol or other substances, pausing is often the better option.

Some antidepressants can reduce libido, make orgasm more difficult or affect arousal. If this happens, discuss alternatives or dose-related options with your prescriber rather than changing medication abruptly. Sleep problems, pain and the pressures of everyday life also deserve attention.

Self-help & coping

PTSD treatment aims to reduce intrusive memories, exaggerated threat responses, avoidance and their effects on your life. Several approaches have convincing clinical evidence; others are useful for particular symptoms or are still experimental.

Treatments with strong clinical evidence

Prolonged exposure (PE). A trained clinician helps you approach traumatic memories and situations you have been avoiding, gradually and in a structured way. Repeatedly encountering reminders in a safe setting can help your brain learn that a memory or familiar sensation does not mean the original danger is happening again. PE has strong evidence for meaningful symptom improvement.

Cognitive processing therapy (CPT). This treatment helps you examine persistent interpretations connected to the trauma—such as expecting danger everywhere or feeling responsible for events outside your control—and develop more accurate, workable ways of responding. It is one of the best-supported PTSD treatments.

EMDR. Eye movement desensitisation and reprocessing is a structured treatment that works with traumatic memories while using bilateral stimulation, commonly guided eye movements. Randomised trials support EMDR as an effective PTSD treatment. Its therapeutic effects are better established than any single proposed explanation of how the eye movements contribute (VA/DoD guideline synopsis, Annals of Internal Medicine, 2024).

Medication for adults. Sertraline, paroxetine and venlafaxine have the strongest guideline support among medicines for overall PTSD symptoms in adults. They can be useful when trauma-focused therapy is unavailable, unsuitable or not preferred. Ask about expected benefits, side effects, sexual functioning, sleep and how progress will be assessed.

Treatment when PTSD begins in childhood

There is good evidence that children and adolescents can recover substantially. Trauma-focused CBT is the best-supported treatment for childhood PTSD. It is adapted to the child’s age and may use drawing, play, talking, practical coping skills and carefully supported work with traumatic memories. A parent or trusted carer can be involved when appropriate and safe. UK clinical guidance recommends trauma-focused CBT for young people with persistent PTSD symptoms; EMDR can be considered for those aged 7–17 who have not benefited from, or cannot engage with, trauma-focused CBT. The same guidance advises against medication as a treatment for PTSD itself in under-18s (NICE PTSD guideline, NG116).

If you are now an adult whose PTSD began in childhood, the adult trauma-focused treatments above are still relevant. The treatment may need to address more than one traumatic memory, long-standing avoidance, dissociation or difficulties that developed in close relationships. You can discuss the sequence and pace with a clinician experienced in childhood trauma.

Treating problems that keep PTSD difficult

Nightmares and sleep disruption. Prazosin may reduce PTSD-associated nightmares for some people, although it has not shown convincing benefits across all PTSD symptoms. Behavioural treatment for persistent insomnia can also be valuable. Your clinician can assess other sleep problems, such as sleep apnoea, and review medicines that affect sleep (VA/DoD guideline, 2023).

Alcohol and other substances. Using alcohol to settle physical arousal or make sleep possible can develop into an additional medical problem. A Swedish population study found that PTSD strongly predicted subsequent alcohol-use disorder (longitudinal registry study, 2023).

If PTSD and alcohol-use disorder have developed together, there is evidence for integrated treatment. In a 2025 randomised trial involving 90 women, a programme combining prolonged exposure with alcohol-treatment techniques produced much larger reductions in PTSD symptoms than standard alcohol relapse prevention alone. Participants had experienced PTSD symptoms for a median of eight years. The trial did not establish superior alcohol outcomes, so both conditions still need direct attention (Persson et al., JAMA Network Open, 2025). If you drink heavily every day, seek medical advice before abruptly stopping because withdrawal can be dangerous.

Practical ways to reduce symptoms between treatment sessions

Ground yourself in the present. Notice where you are, identify ordinary objects around you, feel your feet against the floor or name the current date. This may help during a flashback or a period of dissociation.
Try comfortable, slower breathing. See whether a few minutes reduce muscle tension and the sense of immediate alarm. Avoid techniques that make you dizzy or disconnected.
Protect sleep as a treatment target. Keep track of nightmares, awakenings, alcohol intake and medication effects so you can see what makes sleep better or worse.
Keep some rewarding activity in your week. Exercise, spending time outdoors, hobbies and social contact can support wellbeing and physical health, even when they do not directly treat the core PTSD response.
Measure what changes. Record the frequency of nightmares, how often you avoid an activity, or how strongly your body reacts to a reminder. Small changes over several weeks are easier to recognise than a vague impression of feeling better.

The free PTSD Coach app provides practical tools for understanding symptoms and managing distress. It is a useful supplement, not a replacement for effective clinical treatment.

New biological treatments: MDMA, psilocybin, LSD and ayahuasca

MDMA-assisted therapy has the strongest PTSD trial evidence among these approaches. In a 2023 phase-three randomised study, participants had experienced PTSD for an average of around 16 years. At the end of treatment, 71.2% of those who received MDMA with a structured therapeutic programme no longer met PTSD diagnostic criteria, compared with 47.6% receiving placebo and the same therapy. The difference in symptom improvement was clinically substantial (Mitchell et al., Nature Medicine, 2023).

The results are encouraging, but interpretation is affected by difficulty maintaining blinding, questions about trial conduct and therapist safeguards, and the need for better long-term safety data. US regulators declined approval in 2024 and further regulatory review has continued. This is not an established routinely available treatment in most countries.

Psilocybin-assisted therapy is at an earlier stage. In a July 2026 pilot study, nine of 12 veterans with severe, treatment-resistant PTSD met the study’s remission threshold one month after a programme combining two supervised psilocybin sessions with preparation and follow-up therapy. The improvement is striking, but the study had no placebo group and was designed primarily to examine safety. Larger controlled trials are needed to determine how much benefit comes from psilocybin itself and whether it lasts (Armstrong et al., Communications Medicine, 2026).

Ayahuasca has very preliminary clinical evidence. An eight-person case series involving military veterans found improvements in PTSD symptoms following a three-day intervention, with some benefits persisting at three months. Without a randomised comparison group, the results cannot establish treatment effectiveness (Weiss et al., Psychological Trauma, 2024). Ayahuasca contains DMT and monoamine oxidase inhibitors, creating important interaction risks with some medicines.

LSD is also being studied in psychiatry, including for anxiety, but convincing controlled trials establishing its effectiveness specifically for PTSD are not yet available. Results in anxiety or depression cannot simply be transferred to PTSD.

These approaches deserve serious research. They also require careful screening and clinical supervision: altered states can be overwhelming, and cardiovascular effects, drug interactions and risks in people susceptible to mania or psychosis need consideration. A promising clinical trial is different from evidence that an unsupervised experience or commercial retreat reliably treats PTSD.

Approaches with limited evidence for treating core PTSD symptoms

Yoga, meditation, breathwork and exercise can improve relaxation, fitness or aspects of wellbeing, but evidence that they reliably replace trauma-focused PTSD treatment is considerably weaker. Generic supportive conversation and coping-skills programmes may be welcome, yet do not consistently produce the same reduction in core PTSD symptoms as established trauma-focused therapies. The 2023 VA/DoD guideline recommends against benzodiazepines and cannabis as PTSD treatments because of insufficient benefit and potential harms (VA/DoD guideline synopsis, 2024).

You may find an approach useful for sleep or immediate relaxation without it being an effective treatment for intrusive memories and avoidance. Track those outcomes separately.

How it can be for Them to interact with You

Other people may notice your reactions without knowing what triggered them. A loud noise may make you leave a room abruptly. A crowded restaurant may be exhausting. You might become quiet during an intimate moment, react sharply to a surprise or cancel plans after several bad nights of sleep.

For a partner, friend, colleague or family member, these changes can be confusing or difficult, particularly when they are frequent. Someone close to you may feel shut out or become cautious about what to say. Those effects on relationships are worth discussing directly, while keeping control over what personal experiences you choose to share.

Sometimes a simple explanation is enough: “That noise set off my alarm response. Give me ten minutes, then I’d like to carry on.” In other situations, you might agree on a discreet gesture or signal if that helps you communicate during social occasions. What matters is finding an approach that works naturally between you and the people involved.

If anger, avoidance or substance use has been affecting the relationship, it may help to address those specific patterns as part of treatment. People close to you can offer practical support, but they cannot be expected to provide all the treatment or absorb unlimited distress themselves.

Learn more (the Science)

Genetic susceptibility and neurodevelopment. A multi-ancestry genome-wide association meta-analysis combined data from approximately 1.28 million participants and identified 95 PTSD-associated genomic loci, including 80 new regions. Multiomic integration prioritised 43 candidate causal genes. These included glutamatergic synaptic modulators (GRIA1, GRM8), a calcium-channel gene (CACNA1E), synaptic proteins (PCLO, NCAM1), phosphodiesterase signalling (PDE4B), neuronal development and axon guidance (FOXP2, EFNA5, DCC), and endocrine or immune regulators (ESR1, TRAF3, TANK). The findings implicate multiple biological pathways rather than a single PTSD gene or one neurotransmitter deficit (Nievergelt et al., Nature Genetics, 2024).

Biology before versus after exposure. In a prospective functional-MRI study of 221 police recruits, activity in the dorsal amygdala during anticipation of threat and its functional coupling with the precuneus were associated with later increases in PTSD symptoms after occupational trauma exposure. Other amygdala responses changed in association with exposure itself. Measuring neural functioning before trauma helps distinguish pre-existing susceptibility from changes arising later (Biological Psychiatry, 2025).

Polygenic risk and exposure severity. A prospective longitudinal study of 5,687 World Trade Center responders, with more than 49,000 observations over two decades, found that both inherited polygenic susceptibility and the severity of traumatic exposure contributed to long-term PTSD symptom trajectories. Polygenic scores are useful population-level research measures, but are not yet sufficiently accurate or portable across ancestries and settings to guide individual clinical decisions (Mann et al., Molecular Psychiatry, 2025/2026).

Childhood trauma and gene–environment interaction. In 2026, researchers analysed genetic data, reported traumatic experiences and PTSD symptoms from 144,702 people in two UK cohorts. Genetic associations varied with the type of trauma, and gene–exposure interactions were, on average, stronger for reported childhood than adulthood trauma. Signals included interactions involving FAM120A, ANAPC and SGCD; some were especially associated with childhood neglect. The study supports a model in which inherited susceptibility interacts with developmental timing and the particular exposure. Because trauma histories were self-reported and PTSD was assessed using a brief symptom measure, the results do not yet support individual prediction or specific treatment selection (Knyspel et al., European Journal of Psychotraumatology, 2026).

Threat circuitry and learning. The amygdala, hippocampus, prefrontal cortex, anterior cingulate and connected salience networks coordinate threat detection, contextual memory, autonomic arousal and the regulation of defensive responses. Noradrenergic signalling influences arousal and memory consolidation; glucocorticoid pathways influence stress adaptation; glutamatergic and GABAergic systems contribute to synaptic plasticity, excitation and inhibition. PTSD research investigates altered threat anticipation, fear generalisation, memory reconsolidation and impaired safety learning. There is substantial overlap between people and variation across tasks, so no single activation pattern diagnoses PTSD.

Brain development in childhood PTSD. In a longitudinal MRI study, 27 young people with PTSD and 21 comparison participants were assessed twice, one year apart. The groups differed in patterns of prefrontal-cortex development and in changes over time in prefrontal connectivity with the amygdala and hippocampus. These circuits are involved in threat regulation and contextual memory. The study provides direct evidence that childhood PTSD is associated with measurable differences in developing brain networks, although its small sample does not establish which differences existed before trauma or whether they generalise to everyone (Heyn et al., Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019).

Proteomics, metabolomics and epigenetic ageing. A 2026 study of World Trade Center responders compared thousands of plasma proteins and metabolites in trauma-exposed participants with and without PTSD, identifying signals involving neural extracellular-matrix proteins, immune and metabolic pathways, and molecules including glutamate and serotonin. Such molecular profiles may eventually help characterise biological subtypes, but samples collected after trauma cannot establish which differences preceded it (Nature Communications, 2026). In an independent study of 1,828 veterans, greater PTSD symptom burden was associated with faster DNA-methylation-based biological ageing measures (Bourassa et al., Biopsychosocial Science and Medicine, 2025).

How treatments may change neural responses. Prolonged exposure is commonly understood through inhibitory learning: the brain acquires new information that a remembered or anticipated danger is not occurring in the present situation. CPT targets interpretations and appraisals that maintain arousal and avoidance. EMDR has demonstrated treatment efficacy, while the incremental contributions of bilateral stimulation and specific neural mechanisms remain subjects of investigation. Neuroplasticity provides a framework for studying improvement, but a reduction in symptoms does not require demonstrating a specific change on an individual’s brain scan.

Psychedelic-assisted treatment mechanisms. MDMA increases monoaminergic neurotransmission and has been investigated for effects on fear processing, social connection and tolerance of traumatic-memory recall. Psilocybin and LSD act principally through serotonergic pathways, including 5-HT2A receptor agonism, and may influence network flexibility and plasticity. Ayahuasca contains DMT together with MAO-inhibiting compounds. Mechanistic hypotheses do not establish clinical efficacy. For PTSD, MDMA has randomised phase-three efficacy data; psilocybin and ayahuasca have much smaller, less controlled studies; controlled PTSD-specific evidence for LSD remains inadequate. Future studies need credible comparators, longer follow-up, careful safety monitoring and evidence of which biological profiles benefit most.

What would make a useful precision-medicine biomarker? A clinically useful marker would need to predict an individual’s risk, prognosis or response to a particular treatment in independent, prospective cohorts. Researchers are testing combinations of genetic scores, neural responses, autonomic measurements, hormones, inflammatory markers, metabolomics and longitudinal symptom data. The central question is whether using a measured profile to select treatment improves real outcomes compared with good clinical care. That decisive clinical-utility evidence is still being developed.

Organisations

PTSD UK — accessible information on PTSD and complex PTSD, symptoms and treatment, with guidance relevant to different kinds of trauma. It is an information charity, not a crisis or therapy provider.
US National Center for PTSD — extensive research-based information about treatments, symptoms, relationships and recovery, useful internationally as well as to veterans.
International Society for Traumatic Stress Studies (ISTSS) — international professional society sharing traumatic-stress research and educational resources.
EMDR Europe — professional associations, training and accreditation information for EMDR across European countries.
Trauma Research Foundation — research and education on trauma and developing treatments.
Mind — mental-health information, support options and peer resources in England and Wales.

Availability varies by country. For individual treatment, check the clinician’s qualifications, experience in PTSD and whether they offer an evidence-based approach.

Resources

For a deeper look at the evidence behind this page:

Genomics and biological predisposition: PTSD genome-wide association study, 95 loci — Nature Genetics, 2024; brain responses measured before trauma — Biological Psychiatry, 2025; genetic risk and exposure severity over 20 years — Molecular Psychiatry, 2025/2026.
Childhood PTSD and development: genetic susceptibility interacting with childhood versus adult trauma — European Journal of Psychotraumatology, 2026; 70-trial review of treatment for children and adolescents — JAMA Psychiatry, 2025; recognising PTSD symptoms in children and teens — US National Center for PTSD; NICE guidance on treatment for under-18s.
Life trajectory and longevity: 20-year PTSD symptom trajectories — Nature Mental Health, 2025; nationwide mortality and sibling comparisons — 2026; PTSD and epigenetic ageing — 2025.
Established PTSD treatments: Prolonged exposure versus cognitive processing therapy, 916-person trial — JAMA Network Open, 2022; VA/DoD evidence-based treatment guideline; NICE PTSD treatment recommendations.
PTSD and alcohol: 23-year Swedish registry study of PTSD and alcohol-use disorder; integrated PTSD and alcohol treatment trial — JAMA Network Open, 2025.
New treatment research: MDMA-assisted therapy phase-three study — Nature Medicine, 2023; psilocybin pilot study — Communications Medicine, 2026; ayahuasca case series — Psychological Trauma, 2024.
Practical tools: PTSD Coach; VA treatment companion and self-help apps; EMDR therapist directory.

You can also explore Relatix Health resources for related information on sleep, anxiety, depression and attention. Our aim is to connect scientific findings with useful individual outcomes—not to assume that everyone with the same diagnosis has the same biology or needs the same intervention.

Other people like you

People live with PTSD in very different ways. For some, nightmares and intrusive memories are the main difficulties. Others experience persistent alertness, anger, avoidance, dissociation, physical exhaustion or increasing social isolation. Some people remember precisely when symptoms began; others have lived with them since childhood. Some people are able to keep working while finding home life difficult; others function comfortably with close friends but cannot tolerate certain public places or situations.

Hearing how other people recognise their own patterns, choose treatment and rebuild activities can offer useful ideas. You may be particularly interested in accounts from people whose PTSD lasted many years before they found a treatment that worked, or from those managing PTSD alongside alcohol-use problems, chronic pain or disrupted sleep.

We would also like to learn from your experience. What changes made the most difference to your sleep, relationships, work or physical sense of safety? Did a particular treatment reduce unwanted memories, help you enjoy intimacy or make ordinary activities possible again? Were there approaches that cost time or money without helping?

Understanding these different trajectories and treatment responses is a crucial part of developing better, more personalised care.